Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T08029
(Former ID: TTDI02375)
|
|||||
Target Name |
Complement factor P (CFP)
|
|||||
Synonyms |
Properdin; CFP
Click to Show/Hide
|
|||||
Gene Name |
CFP
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Retinopathy [ICD-11: 9B71] | |||||
2 | Sickle-cell disorder [ICD-11: 3A51] | |||||
Function |
A positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MITEGAQAPRLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLGGGVSVEDCCLNT
AFAYQKRSGGLCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTL EWQLQACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGGHCPGQAQE SEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETRSRKCSAPEPSQKPPGKPCPG LAYEQRRCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDA TRTHICNTAVPCPVDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRC AGQQQDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSM VEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEEL Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | ALXN1820 | Drug Info | Phase 2 | Sickle-cell disorder | [2] | |
2 | CLG561 | Drug Info | Phase 2 | Geographic retinal atrophy | [3] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | CLG561 | Drug Info | [5] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Beta-D-Mannose | Ligand Info | |||||
Structure Description | CirpA1 in complex with pseudo-monomeric Properdin lacking TSR2-3 | PDB:7B26 | ||||
Method | X-ray diffraction | Resolution | 3.40 Å | Mutation | Yes | [6] |
PDB Sequence |
WGPWGPVSPC
269 PVTCGLGQTM279 EQRTCNCAGD299 ATRTHICNTA309 VPCPVDGEWD319 SWGEWSPCIR 329 RNMKSISCQE339 IPGQQSRGRT349 CRGRKFDGHR359 CAGQQQDIRH369 CYSIQHCPLK 379 GSWSEWSTWG389 LCMPPCGPNP399 TRARQRLCTP409 LLPKYPPTVS419 GEKNVTFWGR 434 PLPRCEELQG444 QKLVVEEKRP454 CLHVPACKDP464 E
|
|||||
|
||||||
Ligand Name: Alpha-D-Mannose | Ligand Info | |||||
Structure Description | Crystal Structure of Properdin (TSR domains N1 & 456) | PDB:6S08 | ||||
Method | X-ray diffraction | Resolution | 2.03 Å | Mutation | No | [7] |
PDB Sequence |
> Chain A
SVAGGWGPWG 264 PVSPCPVTCG274 LGQTMEQRTC284 NHPVPQHGGP294 FCAGDATRTH304 ICNTAVPCPV 314 DGEWDSWGEW324 SPCIRRNMKS334 ISCQEIPGQQ344 SRGRTCRGRK354 FDGHRCAGQQ 364 QDIRHCYSIQ374 HCPLKGSWSE384 WSTWGLCMPP394 CGPNPTRARQ404 RLCTPLLPKY 414 PPTVGEKNVT430 FWGRPLPRCE440 ELQGQKLVVE450 EKRPCLHVPA460 CKDPEE > Chain B DPVLCFTQYE 37 ESSGKCKGLL47 GGGVSVEDCC57 LNTAFAYQKR67 SGGLCQPCRS77 PRWSLWSTWA 87 PCSVTCSEGS97 QLRYRRCVGW107 NGQCSGKVAP117 GTLEWQLQAC127 EDQQC |
|||||
|
GLY258[A]
4.305
GLY259[A]
3.733
TRP260[A]
1.509
GLY261[A]
4.121
PRO262[A]
3.617
TRP263[A]
1.511
ARG282[A]
3.016
CYS296[A]
3.520
ALA297[A]
2.790
GLY298[A]
4.765
ARG302[A]
3.151
ASP319[A]
4.314
SER320[A]
3.058
TRP321[A]
1.510
GLY322[A]
3.904
GLU323[A]
2.483
TRP324[A]
1.514
ARG346[A]
2.989
ARG368[A]
3.193
GLY380[A]
4.459
SER381[A]
3.826
TRP382[A]
1.512
GLU384[A]
2.356
TRP385[A]
1.503
SER386[A]
3.688
THR387[A]
2.851
TRP388[A]
1.513
ARG401[A]
3.179
ARG403[A]
2.912
ARG405[A]
4.264
PHE431[A]
4.498
TRP432[A]
3.150
GLY433[A]
4.709
CYS439[A]
4.071
GLU440[A]
3.126
LEU442[A]
3.869
SER81[B]
3.923
LEU82[B]
3.080
TRP83[B]
1.518
ARG100[B]
2.726
ARG102[B]
4.881
|
|||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
Degree | 6 | Degree centrality | 6.45E-04 | Betweenness centrality | 7.85E-05 |
---|---|---|---|---|---|
Closeness centrality | 1.66E-01 | Radiality | 1.26E+01 | Clustering coefficient | 2.00E-01 |
Neighborhood connectivity | 9.67E+00 | Topological coefficient | 1.98E-01 | Eccentricity | 13 |
Download | Click to Download the Full PPI Network of This Target | ||||
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Properdin in complement activation and tissue injury. Mol Immunol. 2013 Dec 15;56(3):191-8. | |||||
REF 2 | ClinicalTrials.gov (NCT05565092) A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease. U.S.National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT02515942) CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA). U.S. National Institutes of Health. | |||||
REF 4 | Clinical pipeline report, company report or official report of Alexion | |||||
REF 5 | Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342. | |||||
REF 6 | Structure and function of a family of tick-derived complement inhibitors targeting properdin. Nat Commun. 2022 Jan 14;13(1):317. | |||||
REF 7 | Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b. Front Immunol. 2019 Sep 4;10:2097. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.